This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Sutent® (sunitinib malate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

mRCC Dosing

The recommended starting dose is 50mg capsule taken orally once daily on a 4 weeks on/ 2 weeks off dosing schedule1. 

Treatment with SUTENT should be continued if the patient is deriving clinical benefit from therapy.

How to take SUTENT

SUTENT is for oral administration. It may be taken with or without food. If a dose is missed, the patient should not be given an additional dose. The patient should take the usual prescribed dose on the following day.1 

Sutent dose modification

SUTENT is available in 3 doses to facilitate dose modification in steps of 12.5mg.

Recommended Starting Dose

 50 mg

1st Dose Reduction

37.5 mg

2nd Dose Reduction

25 mg

3rd Dose Reduction

12.5 mg

Recommended Starting Dose


 50 mg

1st Dose Reduction

37.5 mg

2nd Dose Reduction

25 mg

3rd Dose Reduction

12.5 mg

For GIST and mRCC, dose modifications in 12.5 mg steps may be applied based on individual safety and tolerability. Daily dose should not exceed 75 mg nor be decreased below 25 mg.
For pNET, the recommended dose of Sutent is 37.5 mg taken orally once daily without a scheduled rest period, dose modifications in 12.5mg steps may be applied base on individual safety and tolerability.

For GIST and mRCC only
​​​​​​​Negrier S. Oncology 2012;82:189-196 
Castellano D, et al. Cancer Treat Rev 2013;39:230-240

 SUTENT Summary of Product Characteristics

As with all medications, SUTENT interact with certain drugs. Please refer to the SUTENT Summary of Product Characteristics for a complete list of drug-drug interactions.
AE : Adverse Event 
GIST: Gastrointestinal Stromal Tumour
mRCC: Metastatic Renal Cell Carcinoma
pNET: Pancreatic Neuroendocrine Tumour
References
  1. SUTENT Summary of Product Characteristics. 
  2. Negrier S. Oncology 2012;82:189-196.
    3. Castellano D, et al. Cancer Treat Rev 2013;39:230-240.
PP-SUT-GBR-0665. March 2021

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No